Proteome Sciences (GB:PRM) has released an update.
Proteome Sciences has announced a significant contract win worth over £500,000 with a US biopharmaceutical company to provide mass spectrometry services for a clinical trial. The company’s Chief Commercial Officer, Richard Dennis, cites a rise in customer interest and anticipates continued demand throughout 2024. The work, leveraging Proteome Sciences’ Good Clinical Laboratory Practice accreditation, is expected to be mostly completed within the financial year.
For further insights into GB:PRM stock, check out TipRanks’ Stock Analysis page.
